Zeo ScientifiX, Inc.
ZEOX evidence brief
What we can confirm
- Market Cap:
- $9.0M
What it means
What to watch
Prepared research question
What matters most for ZEOX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZEOX
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company developing biological therapeutics from ethically sourced birth tissue for degenerative diseases and regenerative medicine, with principal products Zofin™ and PPX™.
Key risk: Revenue instability
Market Cap
$9.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Apr 30, 2026.
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company developing biological therapeutics from ethically sourced birth tissue for degenerative diseases and regenerative medicine, with principal products Zofin™ and PPX™.
- Clinical-stage biopharmaceutical company focusing on degenerative diseases and regenerative medicine [sec_mda · as of 2026-06-15].
- Principal products include Zofin™ (amniotic fluid-derived) and Patient Pure X™ (PPX™, autologous) [sec_mda · as of 2026-06-15].
- Total revenue of $2.6M and net income of -$0.1M as of 2026-04-30 [sec].
- Accumulated deficit of $68,731,000 and working capital of $155,000 as of April 30, 2026 [sec_mda · as of 2026-06-15].
- Launched an IRB-approved clinical study for PPX™ in musculoskeletal joint pathologies, enrolling up to 350 patients [sec_mda · as of 2026-06-15].
What works
- Portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells and exosomes [sec_mda · as of 2026-06-15].
- Access to IRB-approved clinical data expected to lower risks for future FDA submissions [sec_mda · as of 2026-06-15].
- Florida's SB 1768 legislation may create new demand for stem cell therapy products by increasing awareness and attracting medical tourists [sec_mda · as of 2026-06-15].
What to weigh
- Company has been unsuccessful in achieving a stabilized source of revenues since July 2015 [sec_mda · as of 2026-06-15].
- Net losses of $997,000 for the six months ended April 30, 2026 and cash used of $609,000 from operating activities [sec_mda · as of 2026-06-15].
- FDA regulations may limit ability to sell products in the U.S. without required licenses; company faces potential adverse regulatory interpretations [sec_mda · as of 2026-06-15].
- Accumulated deficit of $68,731,000 and working capital of only $155,000 as of April 30, 2026 [sec_mda · as of 2026-06-15].
From the filings
Quoted directly from source documents.
Company focus and product portfolio
“clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine”
SEC MD&A · June 15, 2026
Principal product Zofin™
“The Company's principal product is Zofin™, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles.”
SEC MD&A · June 15, 2026
Financial losses and cash usage
“The Company incurred net losses of $997,000 for the six months ended April 30, 2026 and used $609,000 of cash from operating activities during that period.”
SEC MD&A · June 15, 2026
Accumulated deficit and working capital
“the Company had an accumulated deficit of $68,731,000 at April 30, 2026”
SEC MD&A · June 15, 2026
Risks & what to watch (4)›
Key risks
- Revenue instability — Company has been unable to achieve stabilized revenues since July 2015 [sec_mda · as of 2026-06-15].
- FDA regulatory risk — FDA may classify products as requiring licenses, limiting U.S. sales [sec_mda · as of 2026-06-15].
- Low working capital — Working capital of $155,000 as of April 30, 2026 may constrain operations [sec_mda · as of 2026-06-15].
- Clinical trial funding — Sufficient working capital needed to fund clinical studies and FDA submissions [sec_mda · as of 2026-06-15].
What to watch
- Progress of the IRB-approved PPX™ clinical study for musculoskeletal joint pathologies [sec_mda · as of 2026-06-15].
- Company's ability to raise additional working capital to sustain operations [sec_mda · as of 2026-06-15].
- Impact of Florida's SB 1768 and similar legislation on stem cell therapy demand [sec_mda · as of 2026-06-15].
- FDA enforcement actions regarding HCT/P classification of company products [sec_mda · as of 2026-06-15].
Sources: SEC MD&A · Generated October 3, 2026 · How we verify sources →
Run Zeo ScientifiX, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zeo ScientifiX, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Zeo ScientifiX, Inc.?
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company developing biological therapeutics from ethically sourced birth tissue for degenerative diseases and regenerative medicine, with principal products Zofin™ and PPX™.
Who is the CEO of Zeo ScientifiX, Inc.?
Mr. Ian T. Bothwell is the chief executive officer of Zeo ScientifiX, Inc. (ZEOX).
Where is Zeo ScientifiX, Inc. headquartered?
Zeo ScientifiX, Inc. (ZEOX) is headquartered in Davie, FL, United States.
What therapeutic areas does Zeo ScientifiX, Inc. focus on?
Zeo ScientifiX, Inc. develops therapies across Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.